Wellington Management Group
MNPR icon

Wellington Management Group’s Monopar Therapeutics MNPR Stock Holding History

Wellington Management Group’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.55M Sell
174,342
-51,726
-23% -$3.12M ﹤0.01% 1255
2025
Q4 		$14.8M Sell
226,068
-5,395
-2% -$441K ﹤0.01% 1143
2025
Q3 		$18.9M Buy
+231,463
New +$10.3M ﹤0.01% 1048

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group's MNPR Position: Q1 2026 in Review

Wellington Management Group reduced its Monopar Therapeutics (MNPR) stake by 23% in Q1 2026, selling an estimated $3.12M and leaving 174,342 shares worth $9.55M. The position accounts for ﹤0.01% of the portfolio, ranked #1255.

Wellington Management Group first reported a position in MNPR in Q3 2025 and has held it in 3 quarters since. The position peaked at $18.9M in Q3 2025. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • Wellington Management Group held 174,342 shares of Monopar Therapeutics worth $9.55M as of Q1 2026.
  • Wellington Management Group sold 51,726 Monopar Therapeutics shares in Q1 2026, an estimated $3.12M.
  • Monopar Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q1 2026, its #1255 holding.
  • Wellington Management Group first reported a position in Monopar Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Wellington Management Group's Monopar Therapeutics position peaked at $18.9M in Q3 2025.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Wellington Management Group's 13F filing for Q1 2026, filed 15 May 2026.